PE Tech Report

NEWSLETTER

Like this article?

Sign up to our free newsletter

AXA Private Equity sells fine chemicals company CABB to Bridgepoint

AXA Private Equity, the leading European diversified private equity firm, has signed an agreement for the sale of the fine chemicals company CABB to the private equity firm Bridgepoint. The parties agreed not to disclose the purchase price.

 
AXA Private Equity acquired the company headquartered in Sulzbach, Germany in 2007. CABB revenues have doubled to EUR311 million since the takeover by AXA Private Equity. Shortly after the purchase, CABB acquired SF Chem located in Pratteln near Basel, Switzerland with the support of AXA Private Equity. Subsequently, CABB purchased Karavati in India, as it looked to access the Asian market as part of its growth strategy.
 
CABB is one of the world’s leading suppliers of chemical building blocks based on chlorine and acetic acid and the world market leader in monochloroacetic acid (MCAA), an essential component used in a wide variety of applications ranging from herbicides and personal care to the food industry. It is also a leading supplier of custom solutions for international companies engaged in agrochemistry as well as for the global food, pharmaceutical and specialty chemical industries. The company has a total of four production facilities, two of them located in Germany.
 
“Throughout the past few years CABB has grown substantially and is now an even more successful company,” says Christof Namenyi, Managing Director of AXA Private Equity Deutschland. “This is a great example of our commitment to sustainable partnerships with our portfolio companies and investors. Our focus is not on financial engineering, rather on working with management teams to help implement growth strategies and to become leaders in their field.”
 
“AXA Private Equity put its network, capital and expertise to work in order to elevate CABB to a leading position on the global market,” says Martin Wienkenhöver, Chief Executive Officer of CABB. The merger with former Hoechst affiliate SF Chem along with the purchase of Karnavati in India contributed significantly to the execution of the successful growth strategy, Wienkenhöver said. “We remain ambitious for the future growth of our business and look forward to working with our new investor Bridgepoint in continuing the path pursued under AXA Private Equity to realise the full strategic value of the company”, Wienkenhöver adds.

Like this article? Sign up to our free newsletter

MOST POPULAR

FURTHER READING

Featured